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Long-term exposure to circulating platinum 
is associated with late effects of treatment 
in testicular cancer survivors
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The success of cisplatin-based chemotherapy for testicular cancer comes at the price of long-term 
and late effects related to healthy tissue damage. We assessed and modelled serum platinum (Pt) 
decay after chemotherapy and determined relationships between long-term circulating Pt levels 
and known late effects.
Patients and methods
In 99 testicular cancer survivors, treated with cisplatin-based chemotherapy, serum and 24-hour 
urine samples were collected during follow-up (1-13 years after treatment). To build a population 
pharmacokinetic model, measured Pt data were simultaneously analysed, together with cisplatin 
dose, age, weight and height using NONMEM software. Based on this model, area under the 
curve between 1 and 3 years after treatment (Pt AUC 1-3 years) was calculated for each patient. 
Predicted long-term Pt exposure was related to renal function and to late effects of treatment 
assessed median 9 (3-15) years after chemotherapy.
Results
Decay of Pt was best described by a two-compartment model. Mean terminal T1/2 was 3.7 (range 
2.5 -5.2) years. Pt AUC 1-3 years correlated with cumulative cisplatin dose, creatinine clearance before 
and 1 year after treatment. Patients with paraesthesia had higher Pt AUC 1-3 years (30.9 vs 27.0 μg/
L*month) compared to patients without paraesthesia (P = 0.021). Patients with hypogonadism, 
elevated LDL-cholesterol levels or hypertension also had higher Pt AUC 1-3 years
Conclusions
Renal function before and after cisplatin treatment is an important determinant of long-term 
Pt exposure. Known long-term effects of testicular cancer treatment such as paraesthesia, 





Since the introduction of platinum (Pt)-based chemotherapy, metastatic testicular cancer has 
become a curable disease with an excellent prognosis. However, late effects of the treatment may 
compromise the quality of life after treatment.1-3 Several studies have shown that testicular cancer 
survivors are prone to develop cardiovascular morbidity and experience metabolic changes.4, 5 
Cardiovascular risk factors, in particular clustered in the metabolic syndrome, are more prevalent 
in testicular cancer survivors compared to age-matched controls. Already during the first years 
after chemotherapy, a subgroup of testicular cancer survivors appears to develop an adverse 
cardiovascular risk profile.6 The underlying mechanisms have not yet been elucidated.
 A decade ago, Gietema et al. found that long-term circulating Pt levels remained 
detectable up to 20 years after cisplatin combination chemotherapy7. Other studies have 
confirmed the presence of circulating Pt residuals in serum after platinum-based treatment.8, 9 
The role of long-term exposure to circulating Pt in the development of cardiovascular disease in 
testicular cancer survivors is not clear. Moreover, the pharmacokinetic (PK) and pharmacodynamic 
characteristics of long-term decay of Pt are also largely unknown.
 We hypothesised that higher exposure to circulating Pt during follow-up is associated 
with a higher prevalence of late adverse effects of treatment. The primary aim of our study was 
to develop a population PK model to characterise the long-term decay of Pt. This population PK 
model is based on individual cisplatin dose, age, weight, height and body surface area at start 
of treatment combined with measured Pt concentrations in samples collected at various time-
points during follow-up after cisplatin-based chemotherapy for testicular cancer. The second aim 
was to use the PK model to determine the influence of various treatment-related factors on the 
modelled decay of Pt concentrations from individual patients and to determine the association 
between estimated Pt exposure and known long-term effects of cisplatin-based chemotherapy.
Methods
Study population and design
Non-seminomatous testicular cancer patients treated with cisplatin-based chemotherapy at the 
University Medical Centre Groningen between 1988 and 2000 were eligible. Refractory or recurrent 
disease, radiotherapy, a history of cardiovascular events before diagnosis, and psychosocial issues 
were exclusion criteria (figure 1). The Medical Ethics Committee of the hospital approved the 
study protocol and all patients gave their written informed consent.
 Between 1997 and 2002, serum and 24-h urine samples were collected at regular follow-
up visits, starting at least 1 year after treatment. The timing of collection was diverse in order to 
obtain data in different phases of Pt decay. One of the serum samples was taken simultaneously 
with a 24-h urine sample. In total, 240 serum samples from 98 patients (one to three samples 
per patient) were collected and analysed. Median interval between start of chemotherapy and 
date of sample was 5.0 years (range 0.9 -13.2). A single 24-h urine sample was collected from 91 
patients, with a median interval of 6.6 years (range 2.8 -13.2) after chemotherapy.
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Serum creatinine levels were measured before chemotherapy and 1 year after start of 
chemotherapy. Creatinine clearance (CRCL), an indicator of renal function, was calculated using 
the Cockcroft-Gault formula.
 At median 9 years (range 3-15) after chemotherapy a follow-up assessment was 
performed at the outpatient clinic in 96 patients to assess known late effects of treatment, such 
as an adverse metabolic profile, presence of paraesthesia, and Raynaud’s phenomenon.4, 6
Quantification of Pt concentration in serum and urine
Serum and 24-h urine samples were stored at -20 oC until Pt measurement. Pt concentrations 
were measured in serum and urine samples by a sensitive procedure during which high-pressure 
decomposition of samples is followed by an adsorptive voltammetric measurement.10 The 
lower limit of quantification of Pt was 6 pg/g serum. Measurements were done in duplicate; the 
coefficient of variation and day-to-day variation were 6% and 5%, respectively7.
Population pharmacokinetic analysis
The measured serum Pt concentrations and 24-h urinary excretion rates were simultaneously 
analysed by nonlinear mixed effects modelling (NONMEM software, Version VI, ICON Development 
Solutions, Hanover, MD, USA) using a one or two-compartment model. We assumed that the 
treatment period (9 to 12 weeks) was negligible compared to the duration of follow-up. Since a 
major fraction of the dose was excreted in the urine before the first measurement, the PK analysis 
was restricted to the fraction remaining in the body after the pre-measurement phase. An 
apparent bioavailability factor F1 was therefore added as a parameter in the model. We assumed 
that Pt was cleared solely via urinary excretion, so the urinary excretion rate was estimated from 
clearance multiplied by the estimated serum concentration. The first-order conditional estimation 
method was used throughout. PLT Tools (PLTsoft, San Francisco, CA, USA) was used as graphical 
user interface. To evaluate the final model, a bootstrap analysis was performed, based on 1000 
sets of 99 patients each, randomly selected from the available 99 patients, and nonparametric 
95% confidence intervals (CI) were obtained.
Assessment of cardiometabolic status during follow-up
Patients were asked about presence or absence of paraesthesia and Raynaud’s phenomenon. 
Paraesthesia was scored as presence or absence of grade I sensory neuropathy according to 
Common Toxicity Criteria 2.0. It was defined as presence of abnormal cutaneous sensations of 
tingling, numbness, pressure, cold, and warmth that are experienced in the absence of a stimulus. 
Development of Raynaud’s phenomenon after chemotherapy was defined as occurrence of 
peripheral discomfort and at least biphasic skin colour change in fingers or hands (or toes or feet) 
after cold exposition, since start of treatment.
 Body weight and height, waist and hip circumference, and blood pressure were measured 
during a physical examination at the outpatient clinic. Lipids, testosterone, luteinizing hormone 
(LH) and von Willebrand factor (vWF) were measured in blood samples. All blood samples were 
drawn in the morning after an overnight fast.
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 Hypogonadism was defined as serum testosterone <10 nmol/L or LH >10 U/L or use 
of testosterone suppletion (with exclusion of patients using suppletion because of bilateral 
orchidectomy). Increased low-density lipoprotein (LDL) cholesterol was defined as LDL-cholesterol 
>4.1 mmol/L or use of statins (National Cholesterol Education Program - Adult Treatment Panel III 
(NCEP-ATP III)).11 Fat percentage was calculated using the Gallagher formula.12 Hypertension was 
defined as newly diagnosed, i.e. after chemotherapy, blood pressure ≥130/85 mmHg or use of 
antihypertensive medication (metabolic syndrome criteria, American Heart Association/National 
Heart, Lung, and Blood Institute).13
Statistical analysis
Continuous variables were described with median and range. Categorical variables were 
described with counts and proportions. Levels of lipids, insulin, glucose, testosterone and vWF 
were non-normally distributed and were log-transformed for statistical analysis. Univariate 
analysis was performed with the Student’s t-test. Associations between two continuous variables 
were assessed by the Pearson’s correlation coefficient. Linear-by-linear association chi2-test was 
used to test for categorical distributions. Multiple logistic regression analyses on the presence of 
paraesthesia, Raynaud’s phenomenon, hypogonadism, increased LDL cholesterol and increased 
blood pressure were performed to assess the effect of long-term Pt exposure and adjust for 
age, body mass index (BMI) and renal function. All tests were carried out two-sided and were 
conducted at the 0.05 significance level. Statistical analyses were performed using IBM SPSS 
version 20 (IBM, Chicago, IL, USA).
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Years 1988-2000
Patients treated for non-seminomatous 
testicular cancer with cisplatin-based 
chemotherapy (n = 171)
Patients eligible for study participation  
(n = 124)
99 patients willing to participate in study,                     
samples were collected during follow-up at various 
moments:
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(median 6.6 years (range 2.8 - 13.2) after treatment)
Years 2002-2011
96 patients participated in follow-up 
study to assess prevalence of late 
effects of treatment 









Based on long-term platinum 
measurements combined with 
cisplatin dose, weight, height and age 
at start of treatment a population 
pharmacokinetic (PK) model was built
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Prevalence of late effects 
was compared with 
individual Pt exposure
Figure 1. Study population and design. Patients 55 years or older at the start of chemotherapy were excluded 
from the follow-up assessment. One patient was excluded from further analysis after the initial population 




Characteristics of the study population are summarized in Table 1. All participants were 
diagnosed with metastatic non-seminomatous testicular cancer and treated with cisplatin-based 
chemotherapy. Median absolute cumulative dose of cisplatin was 809 mg (range 554-1713). 
Details on prevalence of paraesthesia, Raynaud’s phenomenon and cardiovascular risk factors at 
the follow-up visit are listed in Table 1. Measured serum Pt concentrations are shown in Figure 2. 
Circulating Pt levels declined rapidly between 1 and 3 years after treatment.
Population pharmacokinetic model
In addition to the measured serum Pt concentrations and urinary excretion rates, administered 
cumulative cisplatin dose (mg/m2, converted to amount Pt in mg), age at start of chemotherapy 
(years), body surface area (m2), height (m), and weight (kg) were included in the population PK 
analysis. The observed decay in Pt levels was best described by a two-compartment model with 
lognormally distributed inter-individual variability in CL (clearance), V2 (volume of peripheral 
compartment) and F1 (apparent bioavailability). Inter-individual variability in V1 (volume of central 
compartment) and Q (intercompartmental clearance), or inclusion of demographic covariates 
(including age, weight, height) did not result in significant improvement of the objective function 
value. Proportional residual error in the final model was 34%, which is acceptable and comparable 
with other long-term PK models14. Mean terminal T1/2 was 3.7 (range 2.5 – 5.2) years. The final 
population PK model is summarized in supplementary Table 1.
 Based on the model, the individual Pt concentration curve for each patient was 
calculated using the two-compartment model equation (Ct = F1 * Dose / V1 * (C1 * e 
(-λ1 * t) + C2 * e 
(-λ2 * t))) where C1, C2, λ1, and λ2 are the fractional coefficients and exponents of the corresponding 
bi-exponential equation. The median curve for the total study population is depicted in Figure 
2. Subsequently, based on the model equation, individual Pt concentrations were calculated for 
every patient at different moments in time (supplementary Table 2). The area under the curve 
(AUC, μg/L * months) between 1 and 3 years after chemotherapy (Pt AUC 1-3 years) was calculated 
and used as an estimate of long-term exposure to Pt.
Treatment and renal function as determinants of long-term Pt exposure
The total administered dose cisplatin (mg) correlated significantly with long-term Pt AUC 1-3 years 
(r = .517, P < 0.001) (supplementary Table 3). Age at start of chemotherapy correlated with long-
term Pt AUC, but this correlation disappeared after adjusting for renal function. No correlation was 
found between Pt AUC 1-3 years and weight, BMI and body surface area at start of chemotherapy.
 Median serum creatinine level before chemotherapy was significantly lower than 1 year 
after chemotherapy (74 vs 86 μmol/L, P < 0.001). At the follow-up visit median 9 years (range 3-15) 
after treatment, median serum creatinine was 88 μmol/L. Pt AUC 1-3 years was negatively correlated 
with CRCL before chemotherapy (r = -.213, P = 0.040). Also, Pt AUC 1-3 years correlated negatively 
with CRCL one year after chemotherapy (r = -.272, P = 0.008) and at the follow-up visit (r = -.276, 
P = 0.007). Patients were divided into quartiles based on change in serum creatinine 1 year after 
start in comparison with pre-chemotherapy. Patients in the highest quartile, corresponding with 
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the highest increase in serum creatinine, had a higher Pt AUC 1-3 years (P = 0.037) (supplementary 
Table 3).
Late toxicity and long-term Pt exposure
Paraesthesia and Raynaud’s phenomenon
Presence of paraesthesia and Raynaud’s phenomenon stratified by quartiles of Pt AUC 1-3 years is 
depicted in supplementary Figure 1. Patients who reported persisting paraesthesia at follow-up 
had a higher Pt AUC 1-3 years (Table 2). In a multivariate model including age and BMI at follow-up 
and renal function after 1 year, a higher Pt AUC 1-3 years was associated with an increased risk for 
persisting paraesthesia (Odds Ratio (OR) = 1.07 (95% CI, 1.00 to 1.13), P = 0.043) (supplementary 
Table 4). Pt AUC 1-3 years was not associated with the presence of Raynaud’s phenomenon.
Hypogonadism
Patients with hypogonadism at follow-up had a higher Pt AUC 1-3 years (Table 2). In the multivariate 
logistic regression model, long-term exposure to Pt was significantly associated with 
hypogonadism (OR 1.10 (95% CI 1.02 to 1.18), P = 0.016) (supplementary Table 4).
Hypercholesterolemia
Long-term Pt exposure was higher in patients with increased LDL-cholesterol (Table 2). 
Pt AUC 1-3 years correlated with total cholesterol and LDL-cholesterol in univariate analysis (r = .229, 
P = 0.038 and r = .249, P = 0.022 respectively) (supplementary Table 5). In the multiple logistic 
regression model, a higher long-term exposure to Pt remained significantly associated with an 
increased LDL cholesterol (OR 1.07 (95% CI 1.00 to 1.13), P = 0.040) (supplementary Table 4). No 
correlation between long-term Pt exposure and BMI or fat percentage was found.
Blood pressure
Pt AUC 1-3 years was higher in patients with newly diagnosed, i.e. post-chemotherapy, 
hypertension (Table 2). Systolic blood pressure and pulse pressure correlated with Pt AUC 1-3 years 
(r = .307, P = 0.007 respectively r = .237, P = 0.038) (supplementary Table 5). In the multiple logistic 
regression analysis on hypertension, the association between Pt AUC 1-3 years and hypertension 


























Serum platinum measurements and predicted curves





Figure 2. Circulating serum platinum measurements (n = 240) and predicted curves 1-13 years after 
chemotherapy according to the population pharmacokinetic model. Predicted maximum and minimum are 
curves of the highest and lowest predicted decay based on the model.
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Table 1. Demographics, diagnostic, treatment-related and follow-up characteristics of study participants.
Abbreviations: BEP, bleomycin etoposide cisplatin; EP, etoposide cisplatin; IGCCCG, International Germ Cell Cancer Collaborative 
Group Classification; T, testosterone; LH, luteinizing hormone. Percentages for individual characteristics calculated on total 
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Table 1. Demographics, diagnostic, treatment-related and follow-up characteristics of study participants. 
  Study population characteristics n / median % / range  
  Cohort size 96   
  Age at start chemotherapy (years) 29 17 - 53  
  Age at follow-up (years) 39 23 - 64  
  Year of treatment  1988 - 2000  
  Disease Stage II 51 53%  
  (Royal Marsden Classification) III  5 5%  
 IV  40 42%  
  IGCCCG Risk Group Good  54 56%  
 Intermediate 33 34%  
 Poor  9 9%  
  Chemotherapeutic regimen 4 x BEP  32 33%  
 4 x EP  8 8%  
 3 x BEP / 1 x EP 50 52%  
Another cisplatin-based regimen  6 6%  
  Cumulative cisplatin dose (mg) 809 554 - 1713  
  Cumulative cisplatin dose (mg/m2) 400 275 - 800  
  
   Prevalence of late effects of treatment  
  Persisting paraesthesia 33 35%   
  Raynaud's phenomenon 23 25%   
  Hypogonadism (T < 10 or LH > 10 or suppletion) 19 20%   
  Hypercholesterolaemia (≥ 6.5 mmol/L or statin) 23 25%   
  Increased LDL-cholesterol (≥ 4.1 mmol/L or statin) 37 40%   
  Increased blood pressure (≥ 130/85 or antihypertensive) 63 68%  
 
Abbreviations: BEP, bleomycin etoposide cisplatin; EP, etoposide cisplatin; IGCCCG, International Germ Cell 
Cancer Collaborative Group Classification; T, testosterone; LH, luteinizing hormone. Percentages for individual 
characteristics calculated on total number of participants on whom information was available. 
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Table 2. Comparison of long-term Pt exposure, as documented by the AUC 1-3 years after treatment, in patients 
with or without paraesthesia, hypogonadism or cardiovascular risk factors.
*Defined as testosterone < 10 nmol/L or LH > 10 U/L or suppletion. **Criterion of metabolic syndrome definition according to 
AHA/NHLBI.
Abbreviations: SD, standard deviation; CI, confidence interval.






Table 2. Comparison of long-term Pt exposure, as documented by the AUC 1-3 years after treatment, in patients 
with or without paraesthesia, hypogonadism or cardiovascular risk factors. 
 
 
Pt AUC 1-3 years (µg/L * months) 
     
Persisting paraesthesia No. Mean SD p 
     Absent 61 27.0 7.0 
0.021 
     Present 33 30.9  8.8 
     
Hypogonadism* No. Mean SD p 
Absent 74  27.3 7.6 
0.027 
Present 19  31.8 8.2 
     
LDL-cholesterol No. Mean SD p 
< 4 .1 mmol/L 56 26.7 7.4  
0.022 
≥ 4 .1 mmol/L or medication 37 30.5 8.3 
     
Blood pressure** No. Mean SD p 
< 130/85 mmHg 30 25.7 6.5 
0.039  
≥ 130/85 mmHg or medication 63 29 .0 7.6 
     
Von Willebrand Factor No. Mean SD p 
             < 150 % 70 27.4  7.4  
0.131 
≥ 150 % 21 30.3 9 .0 
     
 
 
*Defined as testosterone < 10 nmol/L or LH > 10 U/L or suppletion. **Criterion of metabolic syndrome definition 












In this study we found that circulating Pt levels after standard cisplatin-based chemotherapy 
for testicular cancer correlate strongly with the cumulative administered cisplatin dose and 
renal function before and after chemotherapy. We found a clear relationship between long-
term circulating Pt levels and well-known long-term and late effects, such as paraesthesia, 
hypogonadism, higher LDL-cholesterol levels and hypertension.
 With data from this cohort we built a population PK model to generate new insights into 
the long-term decay of Pt after cisplatin-based chemotherapy. Decay of Pt was modelled using 
sequential measurements of Pt levels in serum and urine combined with the administered dose 
of cisplatin, age, weight and height at start of chemotherapy. The population modelling approach 
allows the prediction of serum Pt concentrations at any time-point and AUC over any time-period 
for each individual patient, as used in the statistical analysis, irrespective of the actual time points 
of blood and urine sampling. This allowed us to quantify the relationship between estimated 
exposure to Pt, renal function and known late effects of treatment.
 Previously, Gietema et al. detected circulating Pt in serum of patients up to 20 years 
after chemotherapy7. Concentrations of Pt correlated with cisplatin dose and CRCL before 
chemotherapy. Brouwers et al. reported comparable findings in patients with diverse tumour 
types, 0.7–6 years after chemotherapy with cisplatin or oxaliplatin.8 Sprauten et al. quantified Pt 
in serum in a cross-sectional study in 169 testicular cancer patients 4-19 years after treatment.9 
These data indicate an association between long-term circulating Pt levels and severity of 
observed neurotoxicity in testicular cancer survivors.
 Based on our PK model we conclude that renal function, both before and shortly after 
treatment, is a strong determinant of long-term exposure to circulating Pt. In addition, patients 
with a stronger increase in serum creatinine levels 1 year after treatment compared with baseline 
had higher Pt AUCs during follow-up. The relationship between circulating Pt and renal function 
may act both ways: patients with higher Pt levels have relatively more renal damage, which in 
turn decreases clearance. Loss of renal function can persist after treatment for years.15, 16 Recently 
Lauritsen et al. concluded that renal function after treatment is closely related to the number 
of cycles of BEP17. These findings underscore the importance of optimizing renal function 
before treatment, preserving it during treatment and preventing decline in renal function after 
completion of cisplatin treatment.
 Patients reporting persisting paraesthesia median 9 years after treatment had a higher 
Pt AUC than those without paraesthesia. In our study, the collection of sequential serum 
and urine samples enabled us to model exposure to circulating Pt, which is an advantage in 
comparison with the cross-sectional study of Sprauten et al. The exact pathogenesis of long-term 
neuropathy is unknown, but relatively high Pt levels have been found in the dorsal root in post-
mortem studies.18 To which extent levels of circulating Pt correspond with levels in the dorsal 
root is unknown. We did not find a relationship between Pt levels and presence of Raynaud’s 




 Hypogonadism and hyperlipidaemia are frequently observed in testicular cancers 
survivors21, 22, and are especially prevalent in patients treated with cisplatin-containing 
chemotherapy (17-21%)4, 6. The higher Pt levels observed in patients diagnosed with hypogonadism 
and patients diagnosed with hyperlipidaemia could point to long-term toxicity on healthy tissue 
involved in androgen- and lipid metabolism due to Pt residuals. From post-mortem studies in 
cisplatin-treated patients it is known that Pt residuals can be found in fat tissue, bone and a range 
of organs such as liver, kidney and lungs.23, 24
 Direct toxic effects of circulating Pt on blood vessels might result in endothelial activation, 
an inflammatory response or accelerated atherosclerosis. Testicular cancer survivors show signs 
of endothelial damage, such as microalbuminuria, increased plasma levels of endothelial and 
inflammatory marker proteins and increased levels of circulating endothelial cells.25, 26 In vitro 
experiments demonstrate that cisplatin induces alterations in the function of endothelial cells 
regarding proliferation, inflammation and fibrinolysis upon exposure to Pt.27 The association we 
found between blood pressure and Pt exposure indicates that circulating Pt might indeed have a 
long-term toxic effect on endothelial tissue.
 Strong points of this study are the sequential collection of serum and urine samples 
per individual patient, the long-term follow-up and the well-defined phenotype. An inherent 
limitation of our study is that the Pt AUC values are model predicted values.
 Cisplatin-based chemotherapy is an essential part of the successful treatment of 
testicular cancer and is also used as curative treatment in other tumour types, such as head and 
neck cancer and cervical cancer. Treatment-related late effects are inevitable, but the treatment 
strategy should minimize the risk of late morbidity. In cases where cisplatin is administered in an 
adjuvant setting, clinicians should take into account that Pt residuals may result in long-term side 
effects. Due to the potentially beneficial effect on Pt levels and the association with lower long-
term Pt exposure, optimal preservation of renal function – before, during and after treatment – 
should be a priority.
 In conclusion, we found a relationship between long-term Pt exposure in testicular 
cancer survivors and known late effects, such as persistent paraesthesia, hypogonadism, 
hypercholesterolemia and increased blood pressure. This association between healthy tissue 
damage in cancer survivors and long-term Pt exposure should be considered during treatment 
decisions and follow-up care in testicular cancer patients. Hence, further research on healthy 
tissue damage caused by long-term Pt exposure is needed.
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Supplementary Figure 2a. Paresthesia in quartiles based on Pt AUC 1-3 years (P = 0.048, Chi
2-test, 
linear-by-linear association).









Supplementary table 1. Population pharmacokinetic parameters obtained by NONMEM. 
 
Parameter Unit Value 95% CI IIV (%) 
CL L/day 0.0220 0.0197–0.0246 13 
V1 L 6.61 5.20–8.03 - 
Q L/day 0.00531 0.00461–0.00611 - 
V2 L 8.05 6.55–10.17 22 
F1 - 0.000158 0.000137–0.000188 17 
Abbreviations: CL, clearance; V1, volume of central compartment; Q, intercompartmental clearance; V2, 
volume of peripheral compartment; F1, apparent bioavailability (fraction remaining in the body after 






Supplementary table 2. Median estimated Pt concentration at several time-points after chemotherapy based on 
the population pharmacokinetic model. 
 
  
Time-point Median Range 
   
1 year (ng/L) 2876 1723 – 5519 
3 years (ng/L) 391 225 – 939 
5 years (ng/L) 197 113 – 453 
10 years (ng/L) 74 30 – 165 
      
Area Under the Curve (AUC) Median Range 

















Supplementary Table 1. Population pharmacokinetic parameters obtained by NONMEM.
Abbreviations: CL, clearance; V1, volume of central compartment; Q, intercompartmental clearance; V2, volume of peripheral 
compartment; F1, apparent bioavailability (fraction remaining in the body after the pre-measurement phase); CI, confidence 
interval; IIV, inter- individual variability.
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Supplementary table 3. Univariate associations between long-term Pt exposure and treatment characteristics 
and renal parameters, and comparison of Pt exposure in groups based on serum creatinine change. 
 
 
Pt AUC 1-3 years 
  r p n 
Absolute dose cisplatin (mg) 0.517 < 0.001 96 
Relative dose cisplatin (mg/m2) 0.488 < 0.001 96 
Age at chemotherapy 0.210 0.040 96 
Weight pre-chemotherapy 0.060 0.561 96 
BMI pre-chemotherapy -0.041 0.694 96 
BSA pre-chemotherapy 0.156 0.130 96 
      
Serum-creatinine pre-chemotherapy 0.260 0.011 94 
Serum-creatinine after 1 year 0.363 < 0.001 96 
Serum-creatinine at follow-up 0.388 < 0.001 94 
CRCL# pre-chemotherapy -0.213 0.040 94 
CRCL# after 1 year -0.272 0.008 93 
CRCL# at follow-up -0.276 0.007 94 
    
Change in serum creatinine between pre-chemotherapy and 1 year after start of 
chemotherapy, divided in quartile. Median change in highest quartile: +26 µmol/L; 
median change in lower three quartiles: +8 µmol/L.    
 Pt AUC 1-3 years (µg/L * month) 
  n mean SD p 
Highest quartile 23 30.6 6.7   
    0.037 
Lower three quartiles 71 26.9 7.4  
  
 
Abbreviations: AUC, area under the curve; BMI, body mass index; BSA, body surface area; CRCL, creatinine 








Supplementary table 4. Comparison of long-term Pt exposure, as documented by the AUC 1-3 years after 
treatment, in patients with or without paraesthesia, hypogonadism or cardiovascular risk factors. 
 
Chapter 3
Supplementary Table 3. Univariate associations between long-term Pt exposure and treatment 
characteristics and renal parameters, and comparison of Pt exposure in groups based on serum 
creatinine change.
#Based on Cockcroft-Gault formula. 
Abbreviations: AUC, area under the curve; BMI, body mass index; BSA, body surface area; CRCL, creatinine clearance.
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Supplementary Table 4. Comparison of long-term Pt exposure, as documented by the AUC 1-3 years after 
treatment, in patients with or without paraesthesia, hypogonadism or cardiovascular risk factors.
*Defined as testosterone < 10 nmol/L or LH > 10 U/L or suppletion. **Criterion of the metabolic syndrome definition according 
to AHA/NHLBI.
Abbreviations: AUC, area under the curve; SD, standard deviation.
Long-term exposure to circulating platinum
 
Supplementary table 4. Comparison of long-term Pt exposure, as documented by the AUC 1-3 years after 
treatment, in patients with or without paraesthesia, hypogonadism or cardiovascular risk factors. 
 
   
Pt AUC 1-3 years (µg/L * months) 
  
   
      
  Persisting paraesthesia No. Mean SD p   
       Absent 61 27.0 7.0 0.021   
       Present 33 30.9 8.8   




   
  Hypogonadism* No. Mean SD p   
  Absent 74 27.3 7.6 0.027   
  Present 19 31.8 8.2   




   
  LDL-cholesterol No. Mean SD p   
  < 4.1 mmol/L 56 26.7 7.4 0.022   
  ≥ 4.1 mmol/L or medication 37 30.5 8.3   




   
  Blood pressure** No. Mean SD p   
  < 130/85 mmHg 30 25.7 6.5 0.039   
  ≥ 130/85 mmHg or medication 63 29.0 7.6   




   
 Von Willebrand Factor No. Mean SD p  
              < 150 % 70 27.4 7.4 0.131  
 ≥ 150 % 21 30.3 9.0  
   
       
 
Abbreviations: AUC, area under the curve; SD, standard deviation.  *Defined as testosterone < 10 nmol/L or LH > 








Supplementary Table 5. Multiple logistic regression models for paresthesia, hypogonadism, LDL-cholesterol 
and blood pressure at follow-up. Predictors are Pt AUC 1-3 years, and age at follow-up, body mass index at 
follow-up and renal function one year after treatment.
Abbreviations: AUC, area under the curve, CRCL, creatinine clearance; CG, Cockcroft-Gault; CI, confidence interval.




Supplementary Table 6. Univariate associations between long-term Pt exposure and cardiovascular 
and metabolic parameters at follow-up.
Patients using antihypertensives* or statins** excluded.
Abbreviations: AUC, area under the curve; HOMA-IR, homeostatic model assessment insulin resistance.






Supplementary table 6. Univariate associations between long-term Pt exposure and cardiov scular a d 
metabolic parameters at follow-up. 
 
 
        
  Pt AUC 1-3 years (µg/L * month) 
  r p n 
Systolic blood pressure (mmHg)* 0.307 0.007 77 
Diastolic blood pressure (mmHg)* 0.124 0.282 77 
Pulse pressure* 0.237 0.038 77 
von Willebrand Factor (%) 0.140 0.186 91 
     
Body mass index -0.091 0.380 95 
Waist circumference -0.058 0.583 92 
Fat percentage (Gallagher formula) -0.053 0.609 95 
Total cholesterol** 0.229 0.038 83 
LDL-cholesterol** 0.249 0.022 84 
 
Patients usi g an ihypertensives  or statins** excluded.  
 
Abbreviations: AUC, area under the curve; HOMA-IR, homeostatic model assessment insulin 
resistance. 
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